MOUNJARO 5MG KWIKPEN
Item requires a valid prescription
Manufactured By LILLY PRODUCTS
Composition TIRZEPATIDE 5MG
RS 14765.60
MRP RS 16406.20
(10% OFF)
Includes all taxes
Package SIZE
( 2.4ML )
100% Authentic
Products
Free
Shipping*
Products
Return Policy
Description:
Mounjaro 5mg KwikPen
Mounjaro 5mg KwikPen (Tirzepatide 5mg) is a once-weekly subcutaneous injection manufactured by Lilly Products (Eli Lilly), representing the first dose escalation step in the Mounjaro treatment journey for adults with Type 2 Diabetes Mellitus (T2DM) and weight management. Tirzepatide is the world's first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — a breakthrough dual incretin mechanism that delivers superior glycaemic control and meaningful weight reduction. The 5mg dose is used from weeks 5 to 8 of therapy, after completing four weeks on the 2.5mg starter dose, and before progressing to higher maintenance doses. Available from Shabbir Medical Hall at the best price in India, this genuine prescription KwikPen is available online with fast, reliable delivery.
BENEFITS: At the 5mg dose, Tirzepatide begins to exert measurable clinical effects. By activating both GIP and GLP-1 receptors simultaneously, it enhances glucose-dependent insulin secretion, suppresses glucagon production, slows gastric emptying, and promotes satiety — reducing appetite and caloric intake. This dual incretin action produces powerful metabolic improvements even at this early escalation stage. Clinical data from the SURPASS programme show progressive improvements in HbA1c and body weight as dose escalation continues, with the 5mg phase establishing tolerability and initial efficacy before advancing toward the therapeutic maintenance doses.
USAGE OVERVIEW: Mounjaro 5mg is administered as a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm. It is the second step in the mandatory dose escalation schedule, following the 2.5mg starter dose. The user-friendly KwikPen is pre-filled and ready to use with no mixing or dose preparation required. Always inject on the same day each week.
SAFETY OVERVIEW: The most common side effects during dose escalation are gastrointestinal — nausea, vomiting, diarrhoea, and reduced appetite. These are most prominent during the first 4 weeks at each new dose level and typically improve with time. Rare but serious risks include pancreatitis and gallbladder disease. Inform your doctor of all medical conditions before starting.
Uses / Indications:
• Type 2 Diabetes Mellitus (T2DM): Adjunct to diet and exercise to improve glycaemic control in adults — Mounjaro 5mg is the first escalation step, used in weeks 5–8 of therapy
• Dose Escalation Phase: Mounjaro 5mg bridges the 2.5mg tolerability starter dose and the therapeutic maintenance doses (7.5mg and above)
• Cardiovascular Risk Reduction: Tirzepatide across all doses has demonstrated cardiovascular benefits in T2DM patients with established cardiovascular disease
• Weight Management (Obesity / Overweight): As Zepbound (same molecule), Tirzepatide is approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity
ADDITIONAL / EMERGING USES:
• Non-alcoholic steatohepatitis (NASH) / Metabolic Associated Steatotic Liver Disease (MASLD): under clinical investigation
• Obstructive sleep apnoea in obesity: emerging clinical data
• Polycystic ovary syndrome (PCOS) with insulin resistance: off-label, specialist use
• Heart failure with preserved ejection fraction (HFpEF) in obese patients: clinical trials ongoing
Interactions / Warnings:
THYROID C-CELL TUMOUR WARNING: In animal studies, Tirzepatide caused dose-dependent thyroid C-cell tumours. It is UNKNOWN whether this applies to humans. Mounjaro is CONTRAINDICATED in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Report any neck lumps, hoarseness, or difficulty swallowing immediately.
PANCREATITIS: GLP-1/GIP receptor agonists have been associated with acute pancreatitis. Discontinue Mounjaro 5mg immediately if pancreatitis is suspected. Do not restart without physician evaluation.
HYPOGLYCAEMIA: Mounjaro 5mg alone has a low intrinsic risk of hypoglycaemia. Risk significantly increases with concurrent insulin or sulfonylurea. Patients and carers must know hypoglycaemia symptoms and management. Always carry fast-acting glucose (glucose tablets, fruit juice).
DIABETIC RETINOPATHY: Rapid blood sugar improvement may temporarily worsen diabetic retinopathy. Patients with pre-existing retinopathy require ophthalmological monitoring after starting Tirzepatide.
DOSE ESCALATION PACE: If GI side effects at 5mg are not resolving after 4 weeks, discuss with your endocrinologist before advancing to 7.5mg. Your doctor may extend the time at 5mg to improve tolerability. Never self-escalate ahead of your prescribed schedule.
RENAL DISEASE: No dose adjustment required; however, dehydration from GI side effects can trigger acute kidney injury. Maintain adequate hydration, especially during early dose escalation.
TYPE 1 DIABETES: Mounjaro is NOT indicated for Type 1 Diabetes or diabetic ketoacidosis.
ELDERLY USE (≥65 years): No age-specific dose adjustment required, but elderly patients may be more susceptible to GI side effects and dehydration. Monitor hydration and renal function more closely.
Pregnancy interaction:
• Mounjaro 5mg (Tirzepatide) is NOT recommended during pregnancy.
• Animal studies have shown adverse effects on foetal development at clinically relevant doses.
• Tirzepatide should be discontinued at least 2 months before a planned pregnancy due to its long half-life and persistent pharmacological effects.
• Women of childbearing potential must use effective contraception during treatment.
• Inform your doctor immediately if pregnancy is suspected or confirmed.
• Your physician will switch you to insulin (which is safe in pregnancy) to maintain blood sugar control during pregnancy.
BREASTFEEDING:
• It is not known whether Tirzepatide is excreted in human breast milk.
• Breastfeeding is NOT recommended during Mounjaro 5mg treatment as a precautionary measure.
• Discuss temporary cessation and safe alternative feeding options with your physician.
DOCTOR CONSULTATION WARNING:
• Never stop Mounjaro without consulting your endocrinologist or diabetologist. Stopping abruptly may lead to deterioration in blood sugar control. If you are experiencing intolerable side effects, your doctor may slow the escalation pace — not stop treatment entirely.
Expert advice:
1. UNDERSTAND YOUR POSITION IN THE ESCALATION SCHEDULE:
• Mounjaro 5mg is weeks 5–8 of your treatment journey — the first true escalation from the 2.5mg starter dose. This phase is critical for establishing tolerability. Do not rush to the next dose if GI symptoms have not settled. Discuss any persistent side effects with your endocrinologist before advancing to 7.5mg.
2. MANAGING GI SIDE EFFECTS DURING ESCALATION:
• Nausea and reduced appetite are most common during dose transitions. Practical strategies include: eating smaller, low-fat meals; avoiding greasy, spicy, or very sweet foods; staying well hydrated (sip fluids throughout the day); injecting at bedtime so peak nausea occurs during sleep; and eating slowly. These symptoms typically improve within 2–4 weeks at the 5mg dose.
3. INSULIN CO-PRESCRIPTIONS — MONITOR CAREFULLY:
• If you are on basal insulin alongside Mounjaro 5mg, your doctor may have already reduced your insulin dose. Monitor fasting blood glucose daily and report any hypoglycaemic episodes immediately. Never adjust your own insulin dose without physician guidance.
4. ORAL CONTRACEPTIVE INTERACTION:
• Tirzepatide slows gastric emptying, which can reduce absorption of oral contraceptive pills — particularly at each new dose step. Use additional barrier contraception (e.g., condoms) for the first 4 weeks at the 5mg dose level.
5. COLD CHAIN COMPLIANCE:
• Always refrigerate Mounjaro KwikPen immediately upon delivery (2–8°C). Never freeze. If travelling, use an insulated medical pouch. Once removed from the fridge, use within 21 days (below 30°C). Always inspect the solution before injecting.
MONITORING ADVICE:
• Blood glucose (fasting & post-prandial): Monitor regularly throughout escalation phase
• HbA1c: Recheck at 3 months from initiation to assess early glycaemic response
• Body weight: Record weekly; early weight reduction (even 1–2 kg) is a positive sign at 5mg
• Blood pressure: Weight loss may reduce BP — review antihypertensive doses with your doctor
• Kidney function (eGFR / serum creatinine): Baseline and if GI symptoms cause dehydration
• Lipid profile: At baseline and at 3 months — metabolic improvements often appear early
• Thyroid: Report any new neck lumps, hoarseness, or swallowing difficulty immediately
• Diabetic retinopathy: Ophthalmological review recommended within 3–6 months of starting
• Amylase/lipase: If any abdominal pain suggestive of pancreatitis develops
COMPLIANCE TIPS:
• Set a weekly phone alarm for your injection day — same day every week is essential
• Keep a daily log or use a diabetes management app to track injections, blood glucose, and weight
• If nausea is significant, try injecting at night so symptoms peak while you sleep
• Never share your KwikPen — infection risk and dose confusion
• Rotate injection sites weekly: abdomen, outer thigh, upper arm (document site in your log)
SAFETY TIPS:
• Carry glucose tablets at all times if co-prescribed with insulin or sulfonylurea
• Carry a medical alert card noting you are on Tirzepatide — important in emergencies
• Dispose of used KwikPens in a puncture-resistant sharps container; return via pharmacy take-back
• Do not take OTC NSAIDs (ibuprofen, naproxen) freely — particularly when dehydrated from GI side effects, as they can worsen kidney function
Side Effects:
• Nausea (most common — often improves within 4 weeks at each dose level)
• Vomiting
• Diarrhoea
• Constipation
• Reduced appetite / decreased food intake
• Abdominal discomfort or pain
• Dyspepsia (indigestion) and belching
COMMON SIDE EFFECTS (1 in 10 to 1 in 100 people):
• Injection site reactions: redness, bruising, itching, swelling at injection site
• Fatigue and dizziness (particularly in early weeks)
• Hypoglycaemia (low blood sugar) — especially if co-prescribed with insulin or sulfonylureas
• Hair loss (alopecia) — typically related to rapid weight loss rather than the drug directly
• Mild elevated heart rate
SERIOUS SIDE EFFECTS — CONTACT YOUR DOCTOR IMMEDIATELY:
• Acute Pancreatitis: sudden severe upper abdominal pain radiating to the back, with nausea and vomiting — discontinue Mounjaro and seek urgent care
• Gallbladder Disease (cholecystitis / cholelithiasis): right upper abdominal pain, fever, jaundice
• Severe hypoglycaemia: shakiness, cold sweats, confusion, loss of consciousness — higher risk if co-prescribed with insulin or sulfonylurea
• Acute kidney injury: from dehydration secondary to prolonged GI side effects
EMERGENCY WARNING SIGNS — SEEK IMMEDIATE MEDICAL HELP:
• Sudden severe abdominal pain with vomiting (possible pancreatitis)
• Signs of severe allergic reaction: facial swelling, difficulty breathing, rapid heartbeat
• Neck mass, hoarseness, or difficulty swallowing (possible thyroid C-cell tumour — rare)
• Severe dehydration: dizziness, dark urine, inability to keep fluids down
How to use:
• Week 1–4: 2.5mg once weekly (starter/tolerability dose — not therapeutic)
• Week 5–8: 5mg once weekly ← YOU ARE HERE (Mounjaro 5mg KwikPen)
• Week 9–12: 7.5mg once weekly
• Week 13–16: 10mg once weekly
• Week 17–20: 12.5mg once weekly
• Week 21+: 15mg once weekly (maximum maintenance dose)
• Note: Your endocrinologist may keep you at 5mg longer if you are not tolerating escalation or if 5mg achieves adequate glycaemic targets for your individual goals.
HOW TO USE THE KWIKPEN:
• Remove KwikPen from refrigerator 30 minutes before injection and allow to reach room temperature
• Inspect solution — must be clear, colourless to slightly yellow; discard if cloudy or particulate
• Select injection site: abdomen (≥5cm from navel), outer thigh, or upper arm
• Clean skin with alcohol swab; allow to dry completely
• Press KwikPen firmly against skin; press and hold button until injection completes (click sound), then hold for 5 more seconds before removing
• Rotate injection sites each week to prevent skin reactions
TIMING:
• Inject once every 7 days on the same day each week
• Can be taken at any time of day, with or without food
• Missed dose: if next dose is >4 days away, inject as soon as remembered
• If next dose is <4 days away: skip missed dose and resume usual schedule — never double dose
STORAGE:
• Refrigerate at 2°C–8°C (36°F–46°F). Do NOT freeze.
• Can be stored at room temperature (up to 30°C) for up to 21 days once removed from fridge
• Keep in original carton, protected from light
• Single-patient use only — never share. Discard after use. Keep out of reach of children.
How it works:
Mounjaro 5mg KwikPen contains Tirzepatide — the world's first dual GIP/GLP-1 receptor agonist engineered by Eli Lilly with a fatty acid linker enabling once-weekly dosing.
DUAL RECEPTOR MECHANISM:
1. GLP-1 Receptor Agonism:
• Stimulates glucose-dependent insulin secretion from pancreatic beta cells
• Suppresses glucagon release from alpha cells, reducing hepatic glucose output
• Slows gastric emptying, blunting post-meal blood glucose spikes
• Promotes central satiety via hypothalamic GLP-1 receptors, reducing appetite and caloric intake
2. GIP Receptor Agonism (unique differentiator vs semaglutide / liraglutide):
• Synergistically enhances insulin secretion alongside GLP-1 signalling
• Promotes adipocyte lipid metabolism and fat utilisation
• Improves insulin sensitivity in peripheral tissues (muscle and adipose)
• May reduce nausea burden associated with GLP-1 mono-agonism through GIP-mediated pathways
AT THE 5MG DOSE SPECIFICALLY:
• Establishes therapeutic drug levels after the 2.5mg tolerability phase
• Begins delivering meaningful HbA1c reduction and early weight loss effects
• Prepares the GI tract and metabolic response for higher maintenance doses
• GI side effects — while still possible — are typically less severe than at higher doses
CLINICAL CONTEXT:
• SURPASS trials confirmed progressive dose-dependent improvements in HbA1c and body weight
• Tirzepatide was superior to semaglutide 1mg in head-to-head trials at matched doses
• 5mg serves as both an early efficacy dose and a dose-finding step for individual optimisation
Faq for medicine:
Mounjaro 5mg KwikPen (Tirzepatide 5mg) is a once-weekly injectable medication for Type 2 Diabetes in adults. It is the first dose escalation step after the 2.5mg starter, used in weeks 5–8 of therapy. As a dual GIP/GLP-1 receptor agonist, it controls blood sugar and supports progressive weight loss.
2. How does Mounjaro 5mg Tirzepatide KwikPen work?
Tirzepatide 5mg activates both GIP and GLP-1 receptors simultaneously — stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. This dual incretin mechanism at 5mg begins delivering meaningful HbA1c reduction and early weight loss effects.
3. What is the role of Mounjaro 5mg in the dose escalation schedule?
Mounjaro 5mg is the second step in the mandatory Tirzepatide escalation: 2.5mg (weeks 1–4) then 5mg (weeks 5–8), progressing through 7.5mg, 10mg, 12.5mg to the 15mg maximum. The 5mg phase establishes tolerability and early efficacy before advancing to higher therapeutic doses. Never skip steps.
4. What are the side effects of Mounjaro 5mg KwikPen?
Most common: nausea, vomiting, diarrhoea, reduced appetite, constipation — mainly during the dose transition, improving over 2–4 weeks. Serious but rare: acute pancreatitis (severe abdominal pain), gallbladder disease, hypoglycaemia (with insulin). Seek urgent care for sudden severe abdominal pain or allergic reaction signs.
5. Can I buy Mounjaro 5mg KwikPen online at the best price in India?
Yes. Buy Mounjaro 5mg KwikPen online from Shabbir Medical Hall at 10% OFF MRP (Rs 14,765.60 vs Rs 16,406.20). Valid endocrinologist/diabetologist prescription required. Fast cold-chain delivery across Hyderabad, Bangalore, Mumbai, Delhi, and Chennai.
Medicine interaction:
INSULIN & INSULIN SECRETAGOGUES (HIGH RISK — close monitoring required):
• Insulin (rapid, basal, mixed): concurrent use significantly increases hypoglycaemia risk; insulin dose reduction is often required when initiating Tirzepatide
• Sulfonylureas (glibenclamide, glipizide, glimepiride): enhanced hypoglycaemia risk — consider dose reduction of sulfonylurea when starting Mounjaro 5mg
ORAL MEDICATIONS WITH NARROW THERAPEUTIC INDEX:
• Tirzepatide slows gastric emptying, potentially altering absorption of oral medications
• Warfarin / oral anticoagulants: monitor INR; onset of drug absorption may be delayed
• Oral contraceptive pills (OCPs): reduced absorption during dose escalation steps — consider additional barrier contraception for the first 4 weeks at each new dose level
• Levothyroxine, digoxin: monitor drug levels if clinically relevant
ANTIHYPERTENSIVES:
• Progressive weight loss from Tirzepatide may reduce blood pressure — antihypertensive dose reduction may be needed to avoid hypotension
LIPID-LOWERING MEDICINES:
• Improving metabolic profile may alter lipid parameters; statin doses may need periodic review
ALCOHOL:
• Alcohol can worsen GI side effects and increase hypoglycaemia risk with insulin co-use
• Limit alcohol intake during treatment
SUPPLEMENT INTERACTIONS:
• No major documented interactions; always disclose all herbal products and supplements to your pharmacist before starting Mounjaro
